ST. PETERSBURG, Fla.,
March 2, 2021 /PRNewswire/ --
Isleworth Healthcare Acquisition Corp. (NASDAQ: ISLEU) (the
"Company") announced today the closing of its initial public
offering of 20,700,000 units, which included the full exercise of
the underwriters' over-allotment option, at a price to the public
of $10.00 per unit. The units began
trading on the Nasdaq Capital Market under the symbol "ISLEU" on
February 25, 2021.
Each unit consists of one share of common stock and one-half of
one redeemable warrant. Each whole warrant entitles the holder to
purchase one share of common stock at a price of $11.50 per share. Once the securities comprising
the units begin separate trading, the common stock and warrants are
expected to be traded on the Nasdaq Capital Market under the
symbols "ISLE" and "ISLEW," respectively.
I-Bankers Securities, Inc. served as the sole book-running
manager of the offering and Dawson James Securities, Inc. and
Northland Capital Markets acted as co-managers of the offering.
The offering was made only by means of a prospectus. Copies of
the prospectus related to this offering may be obtained from
I-Bankers Securities, Inc. at 535 5th Ave., 4th Floor, New York, NY 10017.
A registration statement relating to the securities was declared
effective by the Securities and Exchange Commission ("SEC") on
February 24, 2021. This press release
shall not constitute an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Isleworth Healthcare Acquisition Corp.
Isleworth Healthcare Acquisition Corp. is a blank check company
organized for the purpose of effecting a merger, share exchange,
asset acquisition, stock purchase, recapitalization,
reorganization, or other similar business combination with one or
more businesses or entities. It intends to focus on a
business combination with a company in the healthcare
industry. We anticipate targeting companies domiciled
in North America and Europe that are developing
assets in the biopharmaceutical and medical technology/medical
device space which aligns with our management team's experience in
operating healthcare companies and in drug and device/technology
development. We have operating expertise in managing large and
high growth businesses and more specifically, in the life sciences
industry. Collectively, we have built, managed, bought and sold
companies or technologies all over the world.
Al Weiss (Chairman, Director), former
President, Worldwide Operations Walt Disney Parks and
Resorts, and Bob Whitehead (CEO, Director), a
long-standing pharmaceutical executive, in the United States and internationally, and in
large and emerging stage companies, will lead the team. The
team includes Dan Halvorson (EVP
& CFO, Director), experienced public and private company
executive in financial planning and operations in the life science,
technology and artificial intelligence industries; Vipul Patel, MD, (Director), a pioneer in the
development and utilization of robotic surgical technologies, and
is connected to many emerging stage med tech and device companies;
Marc Kozin, (Director), led the
development of LEK's life science strategic planning practice, and
has more than 30 years of healthcare M&A experience and serves
on various bioscience boards; Bob
Dahl (Director), formerly Managing Director of Healthcare
Investments at the Carlyle Group and was previously co-head of
healthcare investment banking at Credit Suisse; and Michelle
McKenna (Director), an experienced board member and she has
significant experience in M&A and early stage companies, and as
a C-suite executive of the NFL, she is responsible for the highly
effective Covid-19 contract tracing program across the league.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, are subject to risks and uncertainties, which could
cause actual results to differ from the forward-looking statements,
including those set forth in the risk factors section of the
prospectus used in connection with the Company's initial public
offering. No assurance can be given that the net proceeds of the
offering will be used as indicated. The Company expressly disclaims
any obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in the Company's expectations with respect
thereto or any change in events, conditions or circumstances on
which any statement is based, except as required by law.
Contact:
Dan
Halvorson
Executive Vice President & Chief Financial Officer and Board
Member
dan@isleworthhealthcare.com
View original
content:http://www.prnewswire.com/news-releases/isleworth-healthcare-acquisition-corp-announces-closing-of-207-000-000-initial-public-offering-including-full-exercise-of-underwriter-over-allotment-option-301238917.html
SOURCE Isleworth Healthcare